Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ501MR)

This product GTTS-WQ501MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ501MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3299MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ7047MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ7679MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ6907MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ8344MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ1773MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ794MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ14373MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW